Skip to main content
Erschienen in: Langenbeck's Archives of Surgery 2/2014

01.02.2014 | Review Article

BRAF mutation status in papillary thyroid carcinoma: significance for surgical strategy

verfasst von: P. Miccoli, F. Basolo

Erschienen in: Langenbeck's Archives of Surgery | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

BRAF mutation is probably the only molecular marker acting as a risk factor that is available before surgery: for this reason, soon after it became quite widespread, it seemed an important tool as a guide towards an individualized surgical therapy in papillary thyroid carcinoma.

Purpose

Capsule invasion, multifocality, and lymph node involvement are the most important parameters influencing the choice of surgical strategy in front of small papillary cancers and, in more detail, of micro papillary carcinomas. The relationship between these parameters and the BRAF mutation are closely examined through the more recent literature. Capsular invasion seems to show the strongest correlation with the mutation and this has important correlations, thus suggesting that a more aggressive local surgery might be advisable, whereas the correlation between the mutation and lymph node involvement would be weaker, at least according to the most recent studies.

Conclusions

The personalization of surgical therapy, today, seems easier to achieve thanks to molecular testing. In particular, an important result could be in the short term reduction in the number of completion thyroidectomies following simple lobectomies. Also, post operative radioactivated iodine therapies should be more carefully evaluated and tailored according to BRAF status. A possible flow chart for the decision of the therapeutic approach is proposed in accordance to the results of the literature.
Literatur
1.
Zurück zum Zitat Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954PubMedCrossRef Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954PubMedCrossRef
2.
Zurück zum Zitat Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA (2003) High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454–1457PubMed Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA (2003) High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454–1457PubMed
3.
Zurück zum Zitat Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, Nikiforov YE (2003) BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88:5399–5404PubMedCrossRef Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, Nikiforov YE (2003) BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88:5399–5404PubMedCrossRef
5.
Zurück zum Zitat Kim TY, Kim WB, Song JY, Rhee YS, Gong G, Cho YM, Kim SY, Kim SC, Hong SJ, Shong YK (2005) The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol 63:588–593CrossRef Kim TY, Kim WB, Song JY, Rhee YS, Gong G, Cho YM, Kim SY, Kim SC, Hong SJ, Shong YK (2005) The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol 63:588–593CrossRef
6.
Zurück zum Zitat Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz M, Tufaro AP, Califano JA, Ringel MD, Zeiger MA, Sidransky D, Ladenson PW (2005) BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90:6373–6379PubMedCrossRef Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz M, Tufaro AP, Califano JA, Ringel MD, Zeiger MA, Sidransky D, Ladenson PW (2005) BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90:6373–6379PubMedCrossRef
7.
Zurück zum Zitat Yip I, Nikiforova MN, Carty SE, Yim JH, Stang ML, Tublin MJ, Lebeau SO, Hodak SP, Ogilvie JB, Nikiforov YE (2009) Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. Surgery 146:1215–1233PubMedCrossRef Yip I, Nikiforova MN, Carty SE, Yim JH, Stang ML, Tublin MJ, Lebeau SO, Hodak SP, Ogilvie JB, Nikiforov YE (2009) Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. Surgery 146:1215–1233PubMedCrossRef
8.
Zurück zum Zitat Ugolini C, Giannini R, Lupi C, Salvatore G, Miccoli P, Proietti A, Elisei R, Santoro M, Basolo F (2007) Presence of BRAF V600 in very early stages of papillary thyroid carcinoma. Thyroid 17(5):381–388PubMedCrossRef Ugolini C, Giannini R, Lupi C, Salvatore G, Miccoli P, Proietti A, Elisei R, Santoro M, Basolo F (2007) Presence of BRAF V600 in very early stages of papillary thyroid carcinoma. Thyroid 17(5):381–388PubMedCrossRef
9.
Zurück zum Zitat Basolo F, Torregrossa L, Giannini R, Miccoli M, Lupi C, Sensi E, Berti P, Elisei R, Vitti P, Baggiani A, Miccoli P (2010) Correlation between the BRAF V600 mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 mm: analysis of 1060 cases. J Clin Endocrinol Metab 95:4197–4205PubMedCrossRef Basolo F, Torregrossa L, Giannini R, Miccoli M, Lupi C, Sensi E, Berti P, Elisei R, Vitti P, Baggiani A, Miccoli P (2010) Correlation between the BRAF V600 mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 mm: analysis of 1060 cases. J Clin Endocrinol Metab 95:4197–4205PubMedCrossRef
10.
Zurück zum Zitat Elisei R, Viola D, Torregrossa L, Giannini R, Romei C, Ugolini C, Molinaro E, Agate L, Biagini A, Lupi C, Valerio L, Materazzi G, Miccoli P, Piaggi P, Pinchera A, Vitti P, Basolo F (2012) The BRAF (V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab 97(12):4390–4398PubMedCrossRef Elisei R, Viola D, Torregrossa L, Giannini R, Romei C, Ugolini C, Molinaro E, Agate L, Biagini A, Lupi C, Valerio L, Materazzi G, Miccoli P, Piaggi P, Pinchera A, Vitti P, Basolo F (2012) The BRAF (V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab 97(12):4390–4398PubMedCrossRef
11.
Zurück zum Zitat Hyun SM, Song HY, Kim SY, Nam SY, Roh JL, Han MW, Choi SH (2012) Impact of combined unilateral central neck dissection and hemithyroidectomy in patients with papillary thyroid micro carcinomas. Ann Surg Oncol 19:591–596PubMedCrossRef Hyun SM, Song HY, Kim SY, Nam SY, Roh JL, Han MW, Choi SH (2012) Impact of combined unilateral central neck dissection and hemithyroidectomy in patients with papillary thyroid micro carcinomas. Ann Surg Oncol 19:591–596PubMedCrossRef
12.
Zurück zum Zitat Joo JY, Yoon YH, Choi B, Kim J, Jo YS, Shong M, Koo BS (2012) Prediction of occult central lymph node metastases in papillary thyroid cancer by pre operative BRAF analysis using fine needle aspiration biopsy: a prospective study. J Clin Endocrinol Metab 97:3996–4003PubMedCrossRef Joo JY, Yoon YH, Choi B, Kim J, Jo YS, Shong M, Koo BS (2012) Prediction of occult central lymph node metastases in papillary thyroid cancer by pre operative BRAF analysis using fine needle aspiration biopsy: a prospective study. J Clin Endocrinol Metab 97:3996–4003PubMedCrossRef
13.
Zurück zum Zitat Gandolfi G, Sancisi V, Torricelli F, Ragazzi M, Frasoldati A, Piana S, Ciarrocchi A (2013) Allele percentage of BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression. J Clin Endocrinol Metab 98:E934–E942PubMedCrossRef Gandolfi G, Sancisi V, Torricelli F, Ragazzi M, Frasoldati A, Piana S, Ciarrocchi A (2013) Allele percentage of BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression. J Clin Endocrinol Metab 98:E934–E942PubMedCrossRef
14.
Zurück zum Zitat Dutenhefner SE, Marui S, Santos AB, de Lima EU, Inoue M, Neto JS, Shiang C, Fukushima JT, Cernea CR, Friguglietti CU (2013) BRAF: a tool in the decision to perform elective neck dissection? Thyroid. In press. Dutenhefner SE, Marui S, Santos AB, de Lima EU, Inoue M, Neto JS, Shiang C, Fukushima JT, Cernea CR, Friguglietti CU (2013) BRAF: a tool in the decision to perform elective neck dissection? Thyroid. In press.
15.
Zurück zum Zitat Alzahrani AS, Xing M (2013) Impact of lymph node metastases identified on central neck dissection (CND) on the recurrence of papillary thyroid cancer: potential role of BRAF V600E mutation in defining CND. Endocr Relat Cancer 20:13–22PubMedCentralPubMedCrossRef Alzahrani AS, Xing M (2013) Impact of lymph node metastases identified on central neck dissection (CND) on the recurrence of papillary thyroid cancer: potential role of BRAF V600E mutation in defining CND. Endocr Relat Cancer 20:13–22PubMedCentralPubMedCrossRef
16.
Zurück zum Zitat Xing M, Alzahrani AS, Carson KA et al (2013) Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 309:1493–1501PubMedCentralPubMedCrossRef Xing M, Alzahrani AS, Carson KA et al (2013) Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 309:1493–1501PubMedCentralPubMedCrossRef
17.
Zurück zum Zitat Miccoli P, Pinchera A, Materazzi G, Biagini A, Berti P, Faviana P, Molinaro E, Viola D, Elisei R (2009) Surgical treatment of low and intermediate risk papillary thyroid carcinomas with minimally invasive video assisted thyroidectomy. J Clin Endocrinol Metab 94:1618–1622PubMedCrossRef Miccoli P, Pinchera A, Materazzi G, Biagini A, Berti P, Faviana P, Molinaro E, Viola D, Elisei R (2009) Surgical treatment of low and intermediate risk papillary thyroid carcinomas with minimally invasive video assisted thyroidectomy. J Clin Endocrinol Metab 94:1618–1622PubMedCrossRef
18.
Zurück zum Zitat Lee J, Chung WY (2012) Current status of robotic thyroidectomy and neck dissection using a gasless trans axillary approach. Curr Opin Oncol 24:7–15PubMedCrossRef Lee J, Chung WY (2012) Current status of robotic thyroidectomy and neck dissection using a gasless trans axillary approach. Curr Opin Oncol 24:7–15PubMedCrossRef
19.
Zurück zum Zitat Witt RL, Ferris RL, Pribitkin EA, Sherman SI, Steward DL, Nikiforow YE (2013) Diagnosis and management of differentiated thyroid cancer using molecular biology. Laryngoscope 123:1054–1064 Witt RL, Ferris RL, Pribitkin EA, Sherman SI, Steward DL, Nikiforow YE (2013) Diagnosis and management of differentiated thyroid cancer using molecular biology. Laryngoscope 123:1054–1064
Metadaten
Titel
BRAF mutation status in papillary thyroid carcinoma: significance for surgical strategy
verfasst von
P. Miccoli
F. Basolo
Publikationsdatum
01.02.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Langenbeck's Archives of Surgery / Ausgabe 2/2014
Print ISSN: 1435-2443
Elektronische ISSN: 1435-2451
DOI
https://doi.org/10.1007/s00423-013-1153-7

Weitere Artikel der Ausgabe 2/2014

Langenbeck's Archives of Surgery 2/2014 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.